AstraZeneca’s hyperkalaemia treatment Lokelma has been approved in Europe, a relief to the company after two years of delay to the potential blockbuster. Formerly known as ZS-9, Lokelma (sodium ...

The approval puts Vifor ahead of AstraZeneca, which had hoped to lead the market with its hyperkalaemia candidate, ZS-9. However its drug was rejected for the second time by the FDA in March ...